Cluster 01: Regulatory and Licensing. Pillar guide. Updated May 2026.

Getting MCAP-licensed. A practical guide for Irish aesthetic clinics.

The Medicinal Cannabis Access Programme (MCAP) is the Irish-state pathway for prescribing specific cannabis-based products under defined indications. It does not directly govern the bulk of aesthetic injectables, but a growing number of Irish aesthetic clinics now offer adjacent prescriber services (medicinal-cannabis pathways for chronic pain, anxiety adjunct, oncology adjunct) and the regulatory question lands on the clinic owner regardless. This guide is the practical sequence for a clinic owner already running aesthetic injectables who is now considering MCAP-pathway services.

The honest answer most clinic owners need first: you probably do not need MCAP for the aesthetic side of the practice. You may need it for the adjacent service line. Read on for which.

What MCAP actually covers

MCAP is a Department of Health programme operated under HPRA framework. It permits authorised consultants to prescribe specific cannabis-based products for three indications (spasticity in MS, intractable epilepsy in named cases, chemotherapy-induced nausea where standard treatment has failed). The programme is not a general aesthetic-medicine licence and does not replace IMC or NMBI registration.

What it does change for a clinic owner: if your clinic offers adjacent prescriber services that touch on cannabis-based product prescribing, the prescriber must be MCAP-authorised, the clinic must operate under appropriate dispensing arrangements, and the records-keeping is materially heavier than a standard aesthetic dispatch.

Who needs MCAP authorisation

  • Consultants prescribing cannabis-based products under one of the three named indications.
  • Clinics dispensing or storing cannabis-based products (separate Misuse of Drugs licensing applies).
  • Aesthetic clinics that have started offering chronic-pain adjunct services where the prescriber may consider cannabis-based options.

Aesthetic injectables (HA fillers, polynucleotides, fat-dissolvers) are not MCAP products. They sit under separate HPRA framework where applicable, plus CE-mark and CPNP registration depending on the product class.

The practical sequence for a clinic owner

  1. Confirm the prescriber is on the IMC specialist register for an MCAP-relevant specialty. NMBI nurse-prescribers operate under separate scope rules.
  2. Apply via the Department of Health MCAP team with the prescriber details and indication scope. Allow six to twelve weeks.
  3. Obtain the Misuse of Drugs licence for the clinic premises if dispensing on-site. This is a separate HPRA-administered application.
  4. Implement the records-keeping protocol. Batch tracking, patient prescription record, and reportable-event procedure are non-optional.
  5. Update the clinic's professional indemnity to reflect the additional service line. Most generic aesthetic policies do not cover prescriber services.
The OFAB position. We do not supply MCAP products and we do not provide regulatory advice. We do hold the practical mapping of which authorities own which decision, and we are happy to direct a clinic owner to the right desk inside the HPRA, the IMC, or the Department of Health.

What the regulatory framework looks like in 2026

The HPRA continues to tighten advertising-of-medicines enforcement under ASAI 7th edition. The result for clinic owners is that any service line touching on prescription medicines must operate under stricter advertising rules than the aesthetic side of the practice. Public-facing pages may not describe specific prescription products. Consultations may, with consent and inside an appropriately gated environment.

Common mistakes

  • Confusing MCAP with a general medical-cannabis licence. There is no such Irish licence; MCAP is indication-specific.
  • Assuming the aesthetic-clinic CE-mark and CPNP registrations cover prescriber services. They do not.
  • Running prescriber-service marketing on the same public page as the aesthetic-injectables marketing. ASAI 7th edition treats these as different categories.

Next steps

If you are scoping an adjacent prescriber service, the right starting point is the prescriber's IMC specialty register status, not the product catalogue. The product side is downstream of the credentialing side. Apply for a trade account and we can include a regulatory-mapping conversation in the verification call if helpful.